Synnovation Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities).
Itzhak Zachi Attia, an assistant professor of medicine and co-director of artificial intelligence (AI) in cardiology at Mayo Clinic, has filed for protection of an Al-based tool to detect cardiac amyloidosis (CA) from the analysis of voltage-time data captured from electrocardiograms (ECGs) acquired from a plurality of leads.
Fundamental Pharma GmbH has described TRPM4/NMDA interaction inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis (ALS).
Aligos Therapeutics Inc. has divulged bicyclic compounds acting as viral replication inhibitors reported to be useful for the treatment of hepatitis B (HBV) and hepatitis D virus infections.
Nuevolution A/S has synthesized bromodomain-containing protein 4 (Brd4, HUNK1) inhibitors reported to be useful for the treatment of cancer, hypoxia, fibrosis, autoimmune disease, inflammatory disorders and viral infections.
Shenzhen Forward Pharmaceuticals Co. Ltd. has disclosed fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.
Beigene Ltd. has identified IL-17A/IL-17 receptor A (IL-17RA) interaction inhibitors reported to be useful for the treatment of cancer, psoriasis, rheumatoid arthritis, spondyloarthritis and multiple sclerosis.
Virginia Commonwealth University has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of traumatic brain injury, myocardial infarction, arthritis, diabetes, gout, COVID-19, Alzheimer’s and Parkinson’s disease, among others.
Blueprint Medicines Corp. has identified KIT (c-KIT) (mutant) inhibitors reported to be useful for the treatment of gastrointestinal stromal tumors (GIST).
RSS
